Fortress Biotech, Inc. Operating Lease, Payments
Fortress Biotech, Inc. (FBIO) reported Operating Lease, Payments of $1.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-13
- Fortress Biotech, Inc. operating lease, payments for the quarter ending 2026-06-30 was $777.00K, a 0.00% change year-over-year.
- Fortress Biotech, Inc. operating lease, payments for the quarter ending 2026-03-31 was $782.00K, a 8.22% decline year-over-year.
- Fortress Biotech, Inc. operating lease, payments for the quarter ending 2025-12-31 was $787.00K, a 12.85% decline year-over-year.
- Fortress Biotech, Inc. operating lease, payments for the quarter ending 2025-09-30 was $781.00K, a 12.64% decline year-over-year.
- Fortress Biotech, Inc. operating lease, payments for fiscal 2025 was $3.20M, a 12.34% decline from fiscal 2024.
- Fortress Biotech, Inc. operating lease, payments for fiscal 2024 was $3.65M, a 2.76% increase from fiscal 2023.
- Fortress Biotech, Inc. operating lease, payments for fiscal 2023 was $3.55M, a 2.19% increase from fiscal 2022.
- Fortress Biotech, Inc. operating lease, payments for fiscal 2022 was $3.47M, a 3.18% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $777.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.56M 10-Q · filed 2026-08-13 | $2.35M derived: sum of 3 quarters · filed 2026-08-13 | $3.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $782.00K 10-Q · filed 2026-05-14 | $1.57M derived: sum of 2 quarters · filed 2026-05-14 | $2.35M derived: sum of 3 quarters · filed 2026-05-14 | $3.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.57M derived: sum of 2 quarters · filed 2026-03-31 | $2.35M derived: sum of 3 quarters · filed 2026-08-13 | $3.20M 10-K · filed 2026-03-31 |
| 2025-09-30 | $781.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.56M derived: sum of 2 quarters · filed 2026-08-13 | $2.41M 10-Q · filed 2025-11-14 | $3.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $777.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.63M 10-Q · filed 2026-08-13 | $2.53M derived: sum of 3 quarters · filed 2026-08-13 | $3.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $852.00K 10-Q · filed 2026-05-14 | $1.75M derived: sum of 2 quarters · filed 2026-05-14 | $2.65M derived: sum of 3 quarters · filed 2026-05-14 | $3.58M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.80M derived: sum of 2 quarters · filed 2026-03-31 | $2.73M derived: sum of 3 quarters · filed 2026-03-31 | $3.65M 10-K · filed 2026-03-31 |
| 2024-09-30 | $894.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.82M derived: sum of 2 quarters · filed 2025-11-14 | $2.74M 10-Q · filed 2025-11-14 | $3.64M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $930.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.85M 10-Q · filed 2025-08-14 | $2.75M derived: sum of 3 quarters · filed 2025-08-14 | $3.64M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $920.00K 10-Q · filed 2025-05-15 | $1.82M derived: sum of 2 quarters · filed 2025-05-15 | $2.71M derived: sum of 3 quarters · filed 2025-05-15 | $3.59M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.79M derived: sum of 2 quarters · filed 2025-03-31 | $2.67M derived: sum of 3 quarters · filed 2025-03-31 | $3.55M 10-K · filed 2025-03-31 |
| 2023-09-30 | $890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.78M derived: sum of 2 quarters · filed 2024-11-14 | $2.65M 10-Q · filed 2024-11-14 | $3.51M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $886.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.76M 10-Q · filed 2024-08-13 | $2.62M derived: sum of 3 quarters · filed 2024-08-13 | $3.49M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $876.00K 10-Q · filed 2024-05-15 | $1.73M derived: sum of 2 quarters · filed 2024-05-15 | $2.61M derived: sum of 3 quarters · filed 2024-05-15 | $3.48M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $858.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.73M derived: sum of 2 quarters · filed 2024-03-28 | $2.60M derived: sum of 3 quarters · filed 2024-03-28 | $3.47M 10-K · filed 2024-03-28 |
| 2022-09-30 | $874.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.74M derived: sum of 2 quarters · filed 2023-11-14 | $2.62M 10-Q · filed 2023-11-14 | $3.48M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $870.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.74M 10-Q · filed 2023-08-14 | $2.61M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $871.00K 10-Q · filed 2023-05-15 | $1.74M derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $868.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.37M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $2.50M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.67M derived: sum of 2 quarters · filed 2022-03-28 | $2.51M derived: sum of 3 quarters · filed 2022-03-28 | $2.96M 10-K · filed 2022-03-28 |
| 2020-09-30 | $841.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.68M derived: sum of 2 quarters · filed 2020-11-09 | $2.13M 10-Q · filed 2020-11-09 | $2.94M derived: sum of 4 quarters · filed 2021-04-09 |
| 2020-06-30 | $835.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.29M 10-Q · filed 2020-08-10 | $2.10M derived: sum of 3 quarters · filed 2021-04-09 | $2.75M derived: sum of 4 quarters · filed 2021-04-09 |
| 2020-03-31 | $451.00K 10-Q · filed 2020-05-11 | $1.27M derived: sum of 2 quarters · filed 2021-04-09 | $1.91M derived: sum of 3 quarters · filed 2021-04-09 | $2.69M derived: sum of 4 quarters · filed 2021-04-09 |
| 2019-12-31 | $816.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $1.46M derived: sum of 2 quarters · filed 2021-04-09 | $2.23M derived: sum of 3 quarters · filed 2021-04-09 | $3.00M 10-K/A · filed 2021-04-09 |
| 2019-09-30 | $645.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.42M derived: sum of 2 quarters · filed 2020-11-09 | $2.19M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $773.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.54M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $767.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |